>>>In Wednesday's market monitor at OptionInvestor.com we mentioned that there was some trader talk that Teva Pharmaceutical (NASDAQ:TEVA) $77.43 might be added to the NASDAQ-100. This proves true as the Israeli generic drug maker will join the NASDAQ-100 Index (NDX.X) effective at the beginning of trading November 7, replacing Concord EFS (NASDAQ:CEFT) $14.28, which is moving its listing to the NYSE. Salomon Smith Barney expects indexers to sell a total of 21.5 million CEFT shares and purchase 3.4 million TEVA shares.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.